Mesenchymal Stem Extracellular Vesicles in Various Respiratory Diseases: A New Opportunity
Zijun Hu,Lujian Zhu,Yanglin Zhu,Yejin Xu
DOI: https://doi.org/10.2147/jir.s480345
IF: 4.5
2024-11-27
Journal of Inflammation Research
Abstract:Zijun Hu, 1, &ast Lujian Zhu, 2, &ast Yanglin Zhu, 3 Yejin Xu 2 1 School of Medicine, Shaoxing University, Shaoxing, Zhejiang, People's Republic of China; 2 Department of Infectious Disease, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, People's Republic of China; 3 Department of Hepatobiliary Pancreatic Gastrointestinal Surgery 2, Affiliated Jinhua Hospital of Wenzhou Medical University, Jinhua, Zhejiang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yejin Xu, Department of Infectious Disease, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, People's Republic of China, Email Lung diseases are associated with high morbidity and mortality rates, thereby jeopardizing human health and imposing a great burden on society. Currently, lung diseases are mainly treated with medications, oxygen therapy and mechanical ventilation, but these approaches are unable to effectively reduce the mortality rate. Therefore, lung transplantation remains the ultimate treatment for various chronic lung diseases, but this treatment is also hindered by the limited availability of lung sources, immature technology and a low survival rate after transplantation. With constant changes in the environment, pathogens, type and amount of harmful substances and the prevalence of respiratory diseases, there is an urgent need to identify alternative treatment methods. Research on stem cell therapy has been very successful in recent years, and mesenchymal stem cells (MSCs), together with their secretory bodies, play a significant therapeutic role. Extracellular vesicles of MSCs (MSC-EVs) are also major components of the paracrine secretion of MSCs, including exosomes, microvesicles, and apoptotic bodies, among which exosomes are the most typical. MSC-EVs are believed to be present in various tissues of the human body where they can carry proteins, DNA, RNA and biologically active factors, just to name a few. They can also transmit various biological signals to participate in different biological activities, including the maintenance of homeostasis within the tissue. Several studies have further demonstrated that MSCs and their generated extracellular vesicles play an important role in the treatment of diseases. In this paper, the origin, properties and roles of MSCs and MSC-EVs are reviewed, the mechanisms of different lung diseases, the limitations of current therapeutic options and the roles of MSC-EVs in Chronic Obstructive Pulmonary Disease, asthma, infectious lung disease, lung cancer, pulmonary fibrosis, pulmonary arterial hypertension, and acute lung injury/ acute respiratory distress syndrome are also discussed (Figure 1). In addition, the current limitations and possible future research directions are also discussed in view of providing new ideas for the role of MSC-EVs in the treatment of lung diseases. Keywords: mesenchymal stem cells, exosomes, lung disease, immunomodulation, epithelial mesenchymal transition (EMT), MSC-EVs The lungs, being highly vulnerable organs, are susceptible to injury and various chronic diseases caused by pathogens, harmful substances and environmental changes. Indeed, lung infection is a major cause of acute lung injury/ acute respiratory distress syndrome (ALI/ARDS) which represent two stages of a critically severe and highly mortal disease. 1 Similarly, smoking, air pollution and other factors can induce conditions such as emphysema, interstitial lung disease and lung cancer which can ultimately lead to respiratory failure to death. 2,3 Recently, a large-scale study showed that in 2020–2021, COVID-19 led to a 1.6% decline in the average life expectancy of the global population, with 15.9 million people dying from the pandemic. COVID-19, therefore, posed a serious threat to human health and was a significant burden to healthcare systems. 4 In addition, the outbreak brought respiratory diseases into the limelight, causing widespread fear among people while also generating significant interest among researchers. Conventional treatments based on the use of surfactants, artificial respiratory support, mechanical ventilation and antibiotics/anti-inflammatory drugs only provide symptomatic relief and prolong prognosis. However, they have limited effects on damaged airways, on the clearance of alveolar fluids as well as on other harmful effects resulting from inflammatory reactions. 5 Hence, there is an urgent need to search for new therapeutic options. Figure 1 The origin, types, components, and roles of MSC-EVs in various lung diseases. Note : This figure is originally drawn by Figdraw platform (<u -Abstract Truncated-
immunology